Physician profile
Christopher Davis
NPI 1346565561
$6,900.85
in general payments reported to CMS, 2019-2025
60 companies · $876 in 2025
The $876 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $1,040 · 2021: $1,520 · 2022: $958 · 2023: $771 · 2024: $844 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,490.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,104.38 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $624.44 | 2019-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $404.44 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $381.12 | 2019-2025 | |
| Amgen INC. | $341.71 | 2019-2024 | Tavneos, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.60 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $303.00 | 2019-2025 | Spravato |
| Astellas Pharma US INC | $298.71 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $272.06 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $265.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $223.14 | 2019-2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $175.21 | 2019-2025 | Rexulti |
| Amarin Pharma, INC. | $161.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $159.38 | 2020-2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.18 | 2024-2025 | Caplyta |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.